UA95095C2 - 11 beta-hydroxyandrosta-1,4-diene-3-ones - Google Patents

11 beta-hydroxyandrosta-1,4-diene-3-ones

Info

Publication number
UA95095C2
UA95095C2 UAA200809718A UAA200809718A UA95095C2 UA 95095 C2 UA95095 C2 UA 95095C2 UA A200809718 A UAA200809718 A UA A200809718A UA A200809718 A UAA200809718 A UA A200809718A UA 95095 C2 UA95095 C2 UA 95095C2
Authority
UA
Ukraine
Prior art keywords
hydroxyandrosta
diene
beta
ones
rrepresents
Prior art date
Application number
UAA200809718A
Other languages
English (en)
Inventor
Житен Ранчходбхаи Патель
Гопалкумар Чиманлал Патель
Гаурав Сандживкумар Шетх
Самир Рамешчандра Шах
Санджай Нандлал Мандхане
Тринадха Рао Читтури
Раджаманнар Тхеннати
Original Assignee
Сан Фарма Адвансед Ресьорч Компани Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сан Фарма Адвансед Ресьорч Компани Лимитед filed Critical Сан Фарма Адвансед Ресьорч Компани Лимитед
Publication of UA95095C2 publication Critical patent/UA95095C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0038—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an androstane skeleton, including 18- or 19-substituted derivatives, 18-nor derivatives and also derivatives where position 17-beta is substituted by a carbon atom not directly bonded to a further carbon atom and not being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C07J71/0015—Oxiranes at position 9(11)
UAA200809718A 2006-01-27 2007-01-29 11 beta-hydroxyandrosta-1,4-diene-3-ones UA95095C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN131MU2006 2006-01-27

Publications (1)

Publication Number Publication Date
UA95095C2 true UA95095C2 (en) 2011-07-11

Family

ID=38459436

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200809718A UA95095C2 (en) 2006-01-27 2007-01-29 11 beta-hydroxyandrosta-1,4-diene-3-ones

Country Status (21)

Country Link
US (1) US8785425B2 (ru)
EP (1) EP2004667B1 (ru)
JP (1) JP5097129B2 (ru)
KR (1) KR101390272B1 (ru)
CN (1) CN101384610B (ru)
AP (1) AP2642A (ru)
AR (1) AR059216A1 (ru)
AU (1) AU2007220114B2 (ru)
BR (1) BRPI0706767A2 (ru)
CA (1) CA2637548C (ru)
EA (1) EA017490B9 (ru)
EC (1) ECSP088689A (ru)
ES (1) ES2428066T3 (ru)
IL (1) IL192983A (ru)
MX (1) MX2008009173A (ru)
NZ (1) NZ569867A (ru)
SG (1) SG170049A1 (ru)
TW (1) TWI374147B (ru)
UA (1) UA95095C2 (ru)
WO (1) WO2007099548A2 (ru)
ZA (1) ZA200806366B (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI374147B (en) 2006-01-27 2012-10-11 Sun Pharma Advance Res Company Ltd Novel 11β-hydroxyandrosta-4-ene-3-ones
AU2013202835B2 (en) * 2006-06-14 2015-11-12 Generics [Uk] Limited Process for the preparation of S-fluoromethyl-6,9-difluoro-11-hydroxy-16-methyl-17-propionyloxy-3-oxo-androsta-1, 4-diene-17-carbothioate and intermediates
CA2654644C (en) * 2006-06-14 2014-02-18 Generics [Uk] Limited Novel process and intermediates
JP2012528140A (ja) 2009-05-29 2012-11-12 ファイザー・リミテッド 新規なグルココルチコイド受容体アゴニスト
EP2560634A1 (en) 2010-04-23 2013-02-27 Piramal Enterprises Limited Nitric oxide releasing prodrugs of therapeutic agents
KR101103943B1 (ko) * 2011-12-12 2012-01-12 오수련 무료이용쿠폰을 활용한 제휴사 및 리셀러의 온라인 제휴마케팅 운영방법
WO2013133980A1 (en) * 2012-03-05 2013-09-12 Bausch & Lomb Incorporated Nitroxy derivatives of soft steroids
CA2897571C (en) 2013-01-21 2018-12-18 Apparao Satyam Nitric oxide releasing prodrugs of therapeutic agents containing at least one carboxylic acid group
CA2912400A1 (en) * 2013-05-28 2014-12-04 Sun Pharma Advanced Research Company Limited Methods for treatment of inflammatory conditions using s-[4-(3-fluoro-3-methylbutyryloxy)but-2-ynyl]6.alpha.,9.alpha.-difluoro-17.alpha.-(furan-2-yl)carbonyloxy-11.beta.-hydroxy-16.alpha.-methyl-3-oxoandrosta-1,4-diene-17.beta.-carbothioate
CN106279341A (zh) * 2015-05-11 2017-01-04 正大天晴药业集团股份有限公司 一种糠酸氟替卡松的制备方法
CN109438543B (zh) * 2018-11-28 2020-09-15 广州健康元呼吸药物工程技术有限公司 一种高纯度糠酸氟替卡松的制备方法
CN111662353A (zh) * 2019-03-05 2020-09-15 上海谷森医药有限公司 一种糠酸氟替卡松晶型1的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US392976A (en) * 1888-11-13 Support for spinning-spindles
US300792A (en) * 1884-06-24 John asbeeey nicholson
US3007923A (en) 1959-01-22 1961-11-07 Lab Francais Chimiotherapie Process for the fluorination of 9beta, 11beta-epoxy and 5alpha, 6alpha-epoxy steroids
SE378109B (ru) 1972-05-19 1975-08-18 Bofors Ab
US4188385A (en) * 1978-04-05 1980-02-12 Syntex (U.S.A.) Inc. Thioetianic acid derivatives
PH24267A (en) 1980-02-15 1990-05-29 Glaxo Group Ltd Androstane carbothioates and pharmaceutical compositions containing the same
US6610675B1 (en) * 1980-07-10 2003-08-26 Nicholas S. Bodor Inactive metabolite approach to soft drug design
US4996335A (en) * 1980-07-10 1991-02-26 Nicholas S. Bodor Soft steroids having anti-inflammatory activity
SE449106B (sv) * 1980-07-10 1987-04-06 Otsuka Pharma Co Ltd Steroid med anti-inflammatorisk verkan samt komposition innehallande denna
ZA814440B (en) * 1980-07-10 1982-10-27 Otsuka Pharma Co Ltd Soft steroids having anti-inflammatory activity
DE3260474D1 (en) 1981-02-02 1984-09-06 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
SK89198A3 (en) * 1995-12-29 1999-03-12 Glaxo Group Ltd Lactone derivatives of 17.beta.-carboxy, carbothio and amide androstane derivatives
US5981517A (en) * 1996-05-09 1999-11-09 Soft Drugs, Inc. Androstene derivatives
WO1999001467A2 (en) 1997-06-30 1999-01-14 Glaxo Group Limited Therapeutically active compounds with low systemic activity due to reduce half life
GB0125259D0 (en) * 2001-10-20 2001-12-12 Glaxo Group Ltd Novel compounds
US7208613B2 (en) * 2002-06-20 2007-04-24 Sun Pharmaceutical Industries Limited Synthesis of s-fluoromethyl 6α,9α-difluoro-11β-hydroxy-16α-methyl-17α-propionyloxy-3-oxoandrosta-1,4-diene-17β-carbothioate
GB0225287D0 (en) 2002-10-30 2002-12-11 Glaxo Group Ltd Novel compounds
TWI374147B (en) 2006-01-27 2012-10-11 Sun Pharma Advance Res Company Ltd Novel 11β-hydroxyandrosta-4-ene-3-ones

Also Published As

Publication number Publication date
CA2637548C (en) 2014-09-23
MX2008009173A (es) 2009-01-15
IL192983A0 (en) 2009-02-11
EA017490B1 (ru) 2012-12-28
AU2007220114A1 (en) 2007-09-07
NZ569867A (en) 2011-06-30
ECSP088689A (es) 2008-11-27
WO2007099548A2 (en) 2007-09-07
CA2637548A1 (en) 2007-09-07
AU2007220114B2 (en) 2011-11-10
ES2428066T3 (es) 2013-11-05
JP5097129B2 (ja) 2012-12-12
CN101384610A (zh) 2009-03-11
CN101384610B (zh) 2013-07-17
TWI374147B (en) 2012-10-11
KR20080091813A (ko) 2008-10-14
AR059216A1 (es) 2008-03-19
EA200801596A1 (ru) 2009-04-28
SG170049A1 (en) 2011-04-29
ZA200806366B (en) 2009-08-26
EP2004667A2 (en) 2008-12-24
KR101390272B1 (ko) 2014-05-19
EA017490B9 (ru) 2013-04-30
JP2009524649A (ja) 2009-07-02
EP2004667A4 (en) 2012-07-18
US8785425B2 (en) 2014-07-22
IL192983A (en) 2014-06-30
AP2008004558A0 (en) 2008-08-31
EP2004667B1 (en) 2013-09-04
WO2007099548A3 (en) 2008-10-09
AP2642A (en) 2013-04-15
BRPI0706767A2 (pt) 2011-06-28
TW200804407A (en) 2008-01-16
US20090054388A1 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
UA95095C2 (en) 11 beta-hydroxyandrosta-1,4-diene-3-ones
MY147211A (en) Novel dihydropseudoerythromycin derivatives
UA93910C2 (ru) Алкоксиалкилзамещенные циклические кетоэнолы и средство для борьбы c вредителями
UA94833C2 (en) Substituted bicyclolactams
TW200744588A (en) Pharmaceutical composition for external use
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
PT2310356E (pt) Derivados de adamantildiamida e a sua utilização
AU2008235089A8 (en) Insecticidal aryl isoxazoline derivatives
RS52323B (en) 2'-FLUORO-2'-DEOKSITETRAHIDROURIDINI KAO INHIBITORI CITIDIN DEAMINAZE
MX2007005694A (es) Nuevos derivados de betulina, preparacion y uso de los mismos.
TNSN08407A1 (en) Organic compounds
EA200801959A1 (ru) Высокоразветвленный полипропилен
UA94606C2 (ru) Производные тиоксантина, композиция, которая их содержит, и их применение в терапии
EP2380874A3 (en) Pleuromutilin derivatives for the treatment of diseases mediated by microbes
MY151973A (en) Cyclic depsipeptides
TW200740429A (en) Methods and dosage forms for reducing side effects of carbamate compounds
MY153763A (en) Quinazolinedione derivatives, preparation thereof and therapeutic uses thereof
TNSN08191A1 (en) Kinase inhibitors
WO2007017728A3 (en) Novel heterocyclic compounds
WO2010031832A3 (en) Synergistic combinations of a macrocyclic inhibitor of hcv and a thiophene-2-carboxylic acid derivative
UA97369C2 (ru) Противоопухолевые соединения дигидропиран-2-она и фармацевтическая композиция на их основе
MX2009001578A (es) Lactamas terapeuticas.
WO2008136385A1 (ja) アミド化合物およびその用途
PL1970372T3 (pl) Sole kwasu 9-oksoakrydyno-10-octowego z 1-alkiloamino-1-deoksypoliolami
MY152557A (en) 3-aminocyclopentanecarboxamides as chemokine receptor modulators